A detailed history of Tower Research Capital LLC (Trc) transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,363 shares of MRSN stock, worth $7,068. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,363
Previous 40,760 89.3%
Holding current value
$7,068
Previous $81,000 90.12%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.23 - $2.25 $44,768 - $81,893
-36,397 Reduced 89.3%
4,363 $8,000
Q2 2024

Aug 13, 2024

BUY
$2.0 - $4.45 $79,880 - $177,733
39,940 Added 4870.73%
40,760 $81,000
Q1 2024

May 15, 2024

SELL
$2.16 - $5.94 $51,220 - $140,855
-23,713 Reduced 96.66%
820 $3,000
Q4 2023

Feb 13, 2024

SELL
$1.11 - $2.34 $26,391 - $55,635
-23,776 Reduced 49.22%
24,533 $56,000
Q3 2023

Nov 14, 2023

BUY
$1.06 - $3.91 $43,360 - $159,942
40,906 Added 552.56%
48,309 $61,000
Q2 2023

Aug 14, 2023

SELL
$3.08 - $9.55 $49,424 - $153,248
-16,047 Reduced 68.43%
7,403 $24,000
Q1 2023

May 09, 2023

SELL
$4.0 - $7.02 $52,992 - $93,000
-13,248 Reduced 36.1%
23,450 $96,000
Q4 2022

Feb 10, 2023

BUY
$5.65 - $7.86 $1,627 - $2,263
288 Added 0.79%
36,698 $215,000
Q3 2022

Nov 10, 2022

BUY
$4.63 - $8.0 $129,260 - $223,344
27,918 Added 328.76%
36,410 $246,000
Q2 2022

Aug 15, 2022

BUY
$2.84 - $5.0 $190 - $335
67 Added 0.8%
8,492 $39,000
Q1 2022

May 12, 2022

SELL
$3.74 - $6.63 $42,714 - $75,721
-11,421 Reduced 57.55%
8,425 $34,000
Q4 2021

Feb 14, 2022

BUY
$5.48 - $9.86 $61,118 - $109,968
11,153 Added 128.3%
19,846 $124,000
Q3 2021

Nov 15, 2021

BUY
$8.56 - $14.47 $24,550 - $41,499
2,868 Added 49.24%
8,693 $82,000
Q2 2021

Aug 16, 2021

SELL
$13.28 - $18.07 $35,537 - $48,355
-2,676 Reduced 31.48%
5,825 $79,000
Q1 2021

May 17, 2021

BUY
$15.31 - $26.52 $119,770 - $207,465
7,823 Added 1153.83%
8,501 $137,000
Q4 2020

Feb 16, 2021

SELL
$16.84 - $27.59 $102,942 - $168,657
-6,113 Reduced 90.02%
678 $18,000
Q3 2020

Nov 16, 2020

SELL
$16.2 - $25.7 $44,080 - $69,929
-2,721 Reduced 28.61%
6,791 $126,000
Q2 2020

Aug 13, 2020

BUY
$5.24 - $23.4 $49,842 - $222,580
9,512 New
9,512 $223,000
Q1 2020

May 15, 2020

SELL
$4.41 - $9.28 $3,413 - $7,182
-774 Closed
0 $0
Q4 2019

Feb 07, 2020

SELL
$1.45 - $6.73 $9,851 - $45,723
-6,794 Reduced 89.77%
774 $4,000
Q3 2019

Nov 05, 2019

BUY
$1.54 - $4.2 $6,495 - $17,715
4,218 Added 125.91%
7,568 $12,000
Q2 2019

Aug 13, 2019

BUY
$3.84 - $6.4 $6,912 - $11,520
1,800 Added 116.13%
3,350 $14,000
Q1 2019

May 14, 2019

SELL
$3.51 - $7.3 $32,920 - $68,466
-9,379 Reduced 85.82%
1,550 $8,000
Q4 2018

Feb 14, 2019

BUY
$3.45 - $9.72 $24,660 - $69,478
7,148 Added 189.05%
10,929 $45,000
Q3 2018

Nov 13, 2018

BUY
$10.0 - $19.02 $15,910 - $30,260
1,591 Added 72.65%
3,781 $38,000
Q2 2018

Aug 15, 2018

BUY
$14.2 - $22.68 $31,098 - $49,669
2,190 New
2,190 $39,000
Q4 2017

Feb 09, 2018

SELL
$14.95 - $19.9 $4,529 - $6,029
-303 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$14.8 - $18.06 $4,484 - $5,472
303
303 $5,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $157M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.